Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study.“Dupilumab was the first biologic approved to treat [atopic dermatitis (AD)]; however, after 16 weeks of treatment, fewer than 40% of patients achieve clear or almost clear skin and